Biodexa Pharmaceuticals PLC Announces General Meeting Results

Ticker: BDRX · Form: 6-K · Filed: May 2, 2025 · CIK: 1643918

Biodexa Pharmaceuticals PLC 6-K Filing Summary
FieldDetail
CompanyBiodexa Pharmaceuticals PLC (BDRX)
Form Type6-K
Filed DateMay 2, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-event, filing-update

TL;DR

Biodexa (formerly Midatech) had a General Meeting on May 2nd, results announced.

AI Summary

Biodexa Pharmaceuticals PLC held a General Meeting on May 2, 2025, where it announced results. The company, formerly known as Midatech Pharma Plc, is based in Cardiff, United Kingdom, and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing indicates ongoing corporate activities and governance events for Biodexa Pharmaceuticals PLC, which could impact investor confidence and future strategic decisions.

Risk Assessment

Risk Level: low — The filing is a routine report of a general meeting's results and does not contain significant financial or operational news.

Key Players & Entities

FAQ

What was the purpose of the General Meeting held on May 2, 2025?

The filing states that Biodexa Pharmaceuticals PLC announced results of its General Meeting held on May 2, 2025.

What is Biodexa Pharmaceuticals PLC's former name?

Biodexa Pharmaceuticals PLC was formerly known as Midatech Pharma Plc, with a name change date of June 2, 2015.

Where is Biodexa Pharmaceuticals PLC located?

The company's principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.

Under which SEC Act is this report filed?

This report is filed under the 1934 Act.

Does Biodexa Pharmaceuticals PLC file annual reports under Form 20-F or 40-F?

Biodexa Pharmaceuticals PLC indicates it files annual reports under cover of Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 2, 2025 regarding Biodexa Pharmaceuticals Plc (BDRX).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing